HEPA Archives | BioTuesdays

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Markets

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

February 18, 2021

Executive Moves

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Todd Hobbs, M.D., to the newly created position of chief medical officer, effective Feb. 16, 2021. In this role, Dr. Hobbs will help lead Hepion as it engages with the FDA...

February 10, 2021

Developments

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...

December 30, 2020

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) completed patient dosing in the 75 mg cohort of its Phase 2a ‘AMBITION’ clinical trial, which is evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). In...

December 10, 2020

Developments

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from a translational research study in which its lead drug candidate, CRV431, decreased formation of procoagulant platelets. The company noted that patients with...

December 2, 2020

Developments

DSMB approves continuation of Hepion’s Phase 2a NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that an independent data safety monitoring board (DSMB) approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial to the next dose level cohort. After...

November 18, 2020

Tag - HEPA

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharma closes $88.4-million offering

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

DSMB approves continuation of Hepion’s Phase 2a NASH trial

General

More